![5-((4-(3-carbamoyl-1-(4-methoxy phenyl)-7-oxo-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)phenyl) (nitroso) amino) pentanoic acid](https://veeprho.com/wp-content/uploads/2026/10/5-4-3-carbamoyl-1-4-methoxy-phenyl-7-oxo-1457-tetrahydro-6H-pyrazolo34-cpyridin-6-ylphenyl-nitroso-amino-pentanoic-acid-3094994-84-7-VE0012199-c227-sqr.png "5-((4-(3-carbamoyl-1-(4-methoxy phenyl)-7-oxo-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)phenyl) (nitroso) amino) pentanoic acid")
100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
3094994-84-75-((4-(3-carbamoyl-1-(4-methoxy phenyl)-7-oxo-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)phenyl) (nitroso) amino) pentanoic acid
● In Stock
| Catalogue No.: | VE0012199 |
|---|---|
| CAS No.: | 3094994-84-7 |
| Mol. Formula: | C25H26N6O6 |
| Mol. Weight: | 506.51 g/mol |
Order Online
Additional information on CAS 3094994-84-7
Parent drug
ApixabanIUPAC Name
5-[4-[3-carbamoyl-1-(4-methoxyphen yl)-7-oxo-4,5-dihydropyrazolo[3,4-c]p yridin-6-yl]-N-nitrosoanilino]pentanoic acidPharmacopeial Synonyms
N/ASynonyms
N-Nitroso Apixaban Amino Acid Impurity; Apixaban N-Nitroso Amino Pentanoic Acid ImpuritySmiles
O=C(O)CCCCN(C1=CC=C(N2CCC3=C(N(C4=CC=C(OC)C=C4)N=C3C(N)=O)C2=O)C=C1)N=OInChI
InChI=1S/C25H26N6O6/c1-37-19-11-9-18(10-12-19)31-23-20(22(27-31)24(26)34)13-15-29(25(23)35)16-5-7-17(8-6-16)30(28-36)14-3-2-4-21(32)33/h5-12H,2-4,13-15H2,1H3,(H2,26,34)(H,32,33)Description
5-((4-(3-carbamoyl-1-(4-methoxyphenyl)-7-oxo-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)phenyl)(nitroso)amino)pentanoic acid, CAS 3094994-84-7, is a nitrosamine-related apixaban impurity with molecular formula C25H26N6O6 and molecular weight 506.51 g/mol. The structure contains an N-nitroso amino acid side chain appended to the apixaban scaffold, consistent with formation during nitrosating conditions, residual nitrite exposure, or process-related amine nitrosation. As a potential genotoxic impurity, it falls within the risk-based control concepts of ICH M7 and related nitrosamine guidance. Trace-level characterization commonly requires LC-MS/MS, high-resolution LC-MS, and orthogonal confirmation by impurity profiling methods, with careful control of ionization and fragmentation.Request a Quote
"*" indicates required fields
Other products related to Apixaban and Nitroso impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Rivaroxaban/ N-Nitroso
CAS No. 937-40-6
Cat No. VE006112
